Recombinant Human USAG1 Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 5370-SD
Key Product Details
Product Specifications
Source
Phe24-Ser206, with an N-terminal Met
Purity
Endotoxin Level
N-terminal Sequence Analysis
Predicted Molecular Mass
SDS-PAGE
Activity
When Recombinant Human (rh) USAG1 is coated at 2 μg/mL (100 μL/well), the concentration of rhLRP-6 Fc Chimera (Catalog # 1505-LR) that produces 50% of the optimal binding response is found to be approximately 0.4-2 μg/mL.
Formulation, Preparation and Storage
5370-SD
Formulation | Lyophilized from a 0.2 μm filtered solution in HCl. |
Reconstitution |
Reconstitute at 250 μg/mL in 4 mM HCl.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: USAG1
USAG1 (uterine sensitization‑associated gene 1), also called WISE (Wnt modulator in surface ectoderm) or Ectodin, gene name SOSTDC1, is a secreted, monomeric 26 ‑ 32 kDa glycoprotein of the sclerostin family of BMP antagonists (1 ‑ 3). Human USAG1 cDNA encodes 206 amino acids (aa), including a 23 aa signal sequence and a 183 aa mature protein with a cystine knot domain (2, 3). Mature human USAG1 shares 96 ‑ 98% aa identity with mouse, rat, canine, equine, porcine and bovine USAG1. USAG1 co‑localizes with BMP7 in the developing and adult kidney, especially in renal distal tubule cells postnatally (2, 4). It is also found in ectodermal tissues such as ameloblasts of teeth (for enamel formation), and cells of the dermal papilla (1, 2). USAG1 binds BMP‑2, ‑4, ‑6, and ‑7, sequestering BMPs and making them unavailable for BMP receptor binding (1 ‑ 5). USAG1 also binds LRPs such as LRP6, blocking LRP6 engagement of Wnt (3, 6). In dental mesenchymal cells, USAG1 is proposed to coordinate BMP, Wnt, FGF and SHH signals that regulate apoptosis during tooth development (1, 6, 7). Deletion of USAG1 results in mice with supernumerary teeth, while concurrent decreased expression of LRP5 and LRP6 restores normal tooth configurations (4 ‑ 6, 8). USAG1-/- mice show decreased susceptibility to kidney injury which is reversed by administration of a neutralizing antibody to BMP7 (4). In a mouse model of Alport syndrome, deletion of USAG1 alternates disease progression (7). These results support a proposed USAG1/WISE antagonism of BMP and Wnt signaling pathways in kidney and tooth development. USAG1 expression by uterine luminal epithelium is also associated with the timing and positioning of blastocyst implantation (9).
References
- Laurikkala, J. et al. (2003) Dev. Biol. 264:91.
- Yanagita, M. et al. (2004) Biochem. Biophys. Res. Commun. 316:490.
- Lintern, K.B. et al. (2009) J. Biol. Chem. 284:23159.
- Yanagita, M. et al. (2006) J. Clin. Invest. 116:70.
- Murashima-Suginami, A. et al. (2008) Biochem. Biophys. Res. Commun. 369:1012.
- Ahn, Y. et al. (2010) Development 137:3221.
- Tanaka, M. et al. (2010) J. Clin. Invest. 120:768.
- Kassai, Y. et al. (2005) Science 309:2067.
- Maeda, K. et al. (2007) J. Reprod. Dev. 53:931.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional USAG1 Products
Product Documents for Recombinant Human USAG1 Protein, CF
Product Specific Notices for Recombinant Human USAG1 Protein, CF
For research use only